Abstract:Background and Aims: Coinfection with hepatitis B virus (HBV) and hepatitis C virus (HCV) is common in areas with a high endemic level of both infections.Coinfected patients have more severe liver disease and an increased risk of hepatocellular carcinoma than mono-infected patients.Interferon + ribavirin for 48 weeks in patients with HCV/HBV coinfection demonstrated an HCV sustained viral response (SVR) comparable to that observed in HCV mono-infected patients.Here we present results of a multicentre study with peginterferon-based combination therapy in Taiwan.Methods: Eligible patients had serum ALT 1.5 X ULN and HCV RNA 100,000 copies/mL, with (n = 161) or without (n = 160) detectable HB-sAg.Patients with HCV genotype 1 received 48 weeks of peginterferon alfa-2a plus 1000-1200 mg ribavirin.Patients with HCV genotype non-1 received 24 weeks of peginterferon alfa-2a plus 800 mg ribavirin.The primary efficacy endpoint was sustained HCV RNA clearance (<25 IU/mL) 24 weeks post-treatment (SVR).Secondary endpoints were HBV viral response (<1000 copies/mL), ALT normalisation and HBsAg clearance at end of treatment and 24 weeks post-treatment.Results: HCV SVR was achieved in 73% and 86% of coinfected patients, and in 77% and 88% of monoinfected patients with genotype 1 and genotype non-1 HCV, respectively.68/145 coinfected patients (47%) had detectable HBV DNA at baseline; of these, 56% had undetectable HBV DNA (<1,000 copies/mL) at 24 weeks post-treatment.17/77 patients with undetectable HBV DNA at baseline suffered a rebound at 24 weeks post-treatment.No rebound was associated with an elevation of serum ALT >200 IU/mL, and most of these patients had achieved an HCV SVR.10% of coinfected patients had cleared HBsAg at 24 weeks post-treatment.More monoinfected patients achieved ALT normalisation than coinfected patients 24 weeks post treatment; 70% vs 62% and 78% vs 67% with HCV genotype 1 and genotype non-1, respectively.Conclusion: Combination therapy of peginterferon alfa-2a and ribavirin is effective for treatment of patients dually infected with HCV and HBV.Importantly, a substantial proportion of the dually infected patients achieved HBsAg clearance -an important indicator of long-term treatment success.

Simultaneous Occurrence of Pleural Effusion and Interstitial Pneumonitis after Treatment with Pegylated Interferon for Hepatitis C Virus Infection.

[Clinical Features of Interstitial Pneumonitis Due to Interferon Alpha Therapy for Chronic Hepatitis C].

Diagnosis and Management of Interstitial Pneumonitis Associated with Interferon Therapy for Chronic Hepatitis C

Interstitial pneumonia associated with interferon and ribavirin

Pegylated-interferon alpha (PEG-IFNα)-induced interstitial lung disease in a patient with chronic hepatitis B: A case report and literature review

An Observation on the Effectiveness of the Patient with Chronic Hepatitis C by Combining Interferon and Ribavirin

The clinical analysis of PEG-interferon alpha-2b therapy in 61 cases of HBeAg-positive chronic hepatitis B

Favorable Outcome of Extended Treatment with Adding Pegylated Interferonα-2a to Entecavir for HBeAg-positive Chronic Hepatitis B: a Case Report.

[The Efficacy and Prognostic Predictors of Different Treatment Courses with Pegylated Interferon Α-2A and Ribavirin Combination in Recurrent Chronic Hepatitis C Patients].

A retrospective study of peginterferon plus ribavirin for treatment of chronic hepatitis C in patients who had undergone previous antiviral therapy

697 AN OPEN-LABEL, COMPARATIVE, MULTICENTRE STUDY OF PEGINTERFERON ALFA-2A (40KD) PLUS RIBAVIRIN IN THE TREATMENT OF PATIENTS CHRONICALLY INFECTED WITH HCV/HBV OR HCV ALONE

Dilated Cardiomyopathy and Hypothyroidism Associated with Pegylated Interferon and Ribavirin Treatment for Chronic Hepatitis C: Case Report and Literature Review

Safety and Efficacy of Low Dose Peginterferon-Alpha-2a Combined with Ribavirin Treating Chronic Hepatitis C in Renal Transplant Recipients

Long-term survival and liver-related events after pegylated interferon/ribavirin therapy in HIV-infected patients with chronic hepatitis C

Treatment of Hepatitis C Virus Recurrence after Orthotopic Liver Transplantation by Pegylated Interferona-2A in Combination with Ribavirin

Liver Histopathological Features Influencing HBeAg Seroconversion in Patients with HBeAg-positive Chronic Hepatitis B Responding to Peg-IFN Treatment

910 A PROSPECTIVE, RANDOMIZED STUDY OF EFFICACY AND SAFETY OF PEGINTERFERON ALFA-2A VERSUS ADEFOVIR DIPIVOXIL IN TREATING LAMIVUDINE- RESISTANT HBeAg-POSITIVE CHB

A Randomized, Open-Label Clinical Study of Combined Pegylated Interferon Alfa-2a (40KD) and Entecavir Treatment for Hepatitis B "e" Antigen-Positive Chronic Hepatitis B.

[Peg-Interferon Alfa-2A and Highly Active Antiretroviral Drug Therapy on Hepatitis C Patients with AIDS].

Randomised clinical trial: efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance.

Clinical study on safety of peginterferon α-2b plus ribavirin for treating chronic hepatitis C